Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations – Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus

October 2, 2013

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 2, 2013 /PRNewswire/ –

Today, Investors’ Reports announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN),
Nektar Therapeutics (NASDAQ: NKTR), and Zalicus Inc. (NASDAQ: ZLCS). Today’s readers may
access these reports free of charge – including full price targets, industry analysis and
analyst ratings – via the links below.

Celgene Corporation Research Report

On September 26, 2013, Celgene Corporation’s subsidiary, Celgene International Sarl
(Celgene International) announced that its will present the latest research findings on
apremilast, an oral small-molecule selective inhibitor of phosphodiesterase 4 (PDE4), at
the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health
Professionals (ARHP) annual meeting, to be held from October 25 to October 31, 2013 in San
Diego. The Company informed that the data to be presented include the long-term results
from two Phase III investigational trials, evaluating the treatment with apremilast for
patients with psoriatic arthritis (PALACE 2), as well as in patients with psoriatic
arthritis with skin involvement (PALACE 3). Further, Celgene International stated that the
results from BCT-0001, a Phase II trial, evaluating apremilast in patients with Behcet’s
Disease with active oral ulcers will also be presented. The Full Research Report on
Celgene Corporation – including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at: [

http://www.investorsreports.com/report/2013-09-29/CELG]

Biogen Idec Inc. Research Report

On September 24, 2013, Biogen Idec Inc. (Biogen Idec) announced that it has been named
into the Dow Jones Sustainability World Index (DJSI World). The Company stated that the
recognition makes Biogen Idec the first and only US-based biotech sector firm to be
included in the list. The Company also informed that it has been named to the DJSI North
America for the fourth consecutive year. Further, the Company stated that it has bagged
the top Carbon Disclosure Score for the biotech sector in Carbon Disclosure Project’s
(CDP) Annual Investor Survey. The Full Research Report on Biogen Idec Inc. – including
full detailed breakdown, analyst ratings and price targets – is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-29/BIIB]

Amgen, Inc. Research Report

On September 28, 2013, Amgen, Inc. (Amgen) announced the results from the Phase 3
ASPECCT (’763) trial, which compared Vectibix (panitumumab) to Erbitux (cetuximab) for the
treatment of wild-type KRAS metastatic colorectal cancer in patients who have not
responded to chemotherapy. According to the Company, the study has met its primary
endpoint, demonstrating that panitumumab was non-inferior to cetuximab for overall
survival. Sean E. Harper, M.D., Executive Vice President of Research and Development at
Amgen said, “ASPECCT was a well-conducted and robust Phase 3 trial involving nearly 1,000
patients globally with metastatic colorectal cancer, Colorectal cancer is a devastating
disease and these results provide physicians with important new information about the role
Vectibix can play as they evaluate treatment options.” The Full Research Report on Amgen,
Inc. – including full detailed breakdown, analyst ratings and price targets – is available
to download free of charge at: [http://www.investorsreports.com/report/2013-09-29/AMGN
]

Nektar Therapeutics Research Report

On September 26, 2013, Nektar Therapeutics (Nektar) reported the preliminary topline
results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic
pain in patients with osteoarthritis of the knee. According to the Company, only 9 (3%)
out of the 295 patients under study, were unable to achieve meaningful pain relief with
NKTR-181, while 53 (18%) patients discontinued treatment during the titration period
because of adverse events, while a total of 213 patients achieved an average 40% reduction
in pain and entered the randomized phase of the study. “We were very pleased that this
drug clearly performs as an effective analgesic with only 3% of the patients who received
NKTR-181 unable to titrate to meaningful pain relief,” said Howard W. Robin, President and
CEO of Nektar. “We are carefully evaluating the lack of post-randomization rebound in the
placebo arm in order to design the optimal pivotal trials for this drug. Based upon the
data from this trial, it is clear that NKTR-181 provides pain relief on par with existing
opioids while achieving a very favorable safety profile that differentiates it from
standard opioids.” The Full Research Report on Nektar Therapeutics – including full
detailed breakdown, analyst ratings and price targets – is available to download free of
charge at: [http://www.investorsreports.com/report/2013-09-29/NKTR]

Zalicus Inc. Research Report

On September 27, 2013, Zalicus Inc. (Zalicus) announced that Z160, the Company’s
first-in-class, oral, state-dependent, selective N-type calcium channel modulator in
development for chronic neuropathic pain, has received Orphan Drug designation from the
U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. “The
FDA’s designation of Z160 as having orphan drug status is an important milestone for
Zalicus as we continue the clinical development work required for potential FDA approval
of Z160,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. Zalicus also
informed that it had completed patient enrollment in two Phase 2 clinical studies of Z160
for chronic neuropathic pain indications including postherpetic neuralgia and lumbosacral
radiculopathy on September 3, 2013.The Company added that the top-line results of both
studies are expected in Q4 2013.The Full Research Report on Zalicus Inc. – including full
detailed breakdown, analyst ratings and price targets – is available to download free of
charge at: [http://www.investorsreports.com/report/2013-09-29/ZLCS]

EDITOR NOTES:

        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only
          human and are prone to make mistakes. If you notice any errors or omissions, please
          notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider represented by Namrata Maheshwari, CFA, has only reviewed the
information provided by Equity News Network in this article or report according to the
Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or
interfere in the application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA
Institute.

www.InvestorsReports.com [http://www.InvestorsReports.com ]

SOURCE Investors’ Reports


Source: PR Newswire